FK614 is an orally active, potent, selective PPARγ modulator (SPPARM). FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is a nonthiazolidinedione insulin sensitizer. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes.

Product information

CAS Number: 193012-35-0

Molecular Weight: 468.40

Formula: C21H23Cl2N3O3S

Chemical Name: 1-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(pentane-1-sulfonyl)-1H-1,3-benzodiazole-6-carboxamide

Smiles: CC1=NC2=CC=C(C=C2N1CC1=CC=C(Cl)C=C1Cl)C(=O)NS(=O)(=O)CCCCC

InChiKey: UYGZODVVDUIDDQ-UHFFFAOYSA-N

InChi: InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)15-7-9-19-20(11-15)26(14(2)24-19)13-16-6-8-17(22)12-18(16)23/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

FK614 (0.1~10000 nM; 24 hours; CV-1 cells) activates PPARγ-dependent transcription in a concentration-dependent manner. FK614 (0~0.1 μM; 5 days; 3T3-L1 adipocytes) makes triglyceride content increased in a concentration-dependent manner. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is an insulin sensitizer potentially for treatment of postherpetic neuralgia.

In Vivo:

FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level. FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance.

Products are for research use only. Not for human use.